In No. 11 of the Cannabis Commerce + Chemistry Podcast, host Curt Robbins from Higher Learning LV and co-hosts John Bailey from the Mindset Genesis and Dena Putnam from Leafwize Naturals are joined by guest Hart Steinfeld from SNDL in Calgary, Canada to discuss a 2021 research study pertaining to the potential efficacy of cannabis for Parkinson's disease.
Guest Steinfeld shares his views of this important German research study and how he approaches the topic of employee education, particularly at the retail level where it is rigorously regulated by Canadian authorities, at SNDL as Manager of Cannabis Education and Training.
This weekly 30-minute podcast is targeted at cannabis and hemp industry professionals and is strategically free of profanity and crude dialog.
🎧 Listen to C3 Podcast
This weekly 30-minute podcast is targeted at cannabis and hemp industry professionals and is strategically free of profanity and crude dialog. This audio session was edited for length and clarity.
To better understand cannabis for Parkinson's disease, listen now at Higher Learning LV, on Apple Podcasts or Spotify, and most other major podcasting platforms (including Amazon Music, Anchor, Google Podcasts, iHeart Radio, Pandora, and Stitcher).
Study Summary: Cannabis for Parkinson's Disease
This weekly audio roundtable discusses a different topic each week that is of importance to the hemp and cannabis industries. For this week's episode, the following article was the topic of discussion that was shared with participants prior to the capture of the episode.
A February 2021 peer-reviewed research study entitled "Cannabis in Parkinson's Disease: The Patients' View" that was published in the Journal of Parkinson's Disease and conducted in Germany had the stated objective of assessing the Parkinson's patient community's "perception of medical cannabis and patients' experience with medical cannabis."
The design of this study was that of a questionnaire-based survey that "evaluated general knowledge and interest in medical cannabis, as well as the frequency, modalities, efficacy, and tolerability of application." Study participants were located throughout the nation of Germany and all were members of the German Parkinson Association.
What is Parkinson's Disease?
According to the Mayo Clinic, Parkinson's disease is "a progressive disorder that affects the nervous system and the parts of the body controlled by the nerves." It reports that the onset of symptoms begins slowly and that it may be "a barely noticeable tremor in just one hand."
One of the major symptoms of Parkinson's is tremors, but "the disorder may also cause stiffness or slowing of movement."
One of the major symptoms of Parkinson's is tremors, but "the disorder may also cause stiffness or slowing of movement," according to the clinic. It listed other symptoms, including a lack of facial expression, reduced mobility, and speech that "may become soft or slurred."
Because it is progressive in nature, Parkinson's disease symptoms "worsen as [the] condition progresses over time." Unfortunately, there is no known cure for Parkinson's.
A total of 1,348 questionnaires (surveys) were collected and analyzed regarding cannabis for Parkinson's disease. Of these survey responses:
51 percent of participants were aware of the legality of medical cannabis in Germany.
28 percent were aware that various consumption avenues ("routes of administration") are available for cannabis, including smoking, vaporization, edibles, sublingual tinctures, transdermal patches, and others).
Read the full article.
Like what you just read? Check out our new Cannabis for Cancer Hub that features links to all of our articles about marijuana for cancer.